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SUMMARY
IkB kinase/nuclear factor kB (IKK/NF-kB) signaling exhibits important yet opposing functions in hepatocar-
cinogenesis. Mice lacking NEMO in liver parenchymal cells (LPC) spontaneously develop steatohepatitis and
hepatocellular carcinoma (HCC) suggesting that NF-kB prevents liver disease and cancer. Here, we show
that complete NF-kB inhibition by combined LPC-specific ablation of RelA, c-Rel, and RelB did not pheno-
copy NEMO deficiency, but constitutively active IKK2-mediated NF-kB activation prevented hepatocellular
damage and HCC in NEMOLPC-KO mice. Knock-in expression of kinase inactive receptor-interacting protein
kinase 1 (RIPK1) prevented hepatocyte apoptosis andHCC,while RIPK1 ablation induced TNFR1-associated
death domain protein (TRADD)-dependent hepatocyte apoptosis and liver tumors in NEMOLPC-KO mice,
revealing distinct kinase-dependent and scaffolding functions of RIPK1. Collectively, these results show
that NEMO prevents hepatocarcinogenesis by inhibiting RIPK1 kinase activity-driven hepatocyte apoptosis
through NF-kB-dependent and -independent functions.
INTRODUCTION
Liver cancer is the fifth most common cancer in men and the
seventh in women (El-Serag, 2011; Shariff et al., 2009). Hepato-
cellular carcinoma (HCC), the most prominent primary liver
cancer, usually develops in the presence of cirrhosis and chronic
inflammatory conditions resulting from hepatitis B virus (HBV) or
hepatitis C virus (HCV) infections, alcoholic and non-alcoholic
Significance
Pathways regulating cell survival, cell death, and inflammation play a key role in the maintenance of liver homeostasis and
the pathogenesis of chronic liver disease and cancer. Caspase-dependent apoptosis and receptor-interacting protein (RIP)
kinase-dependent necroptosis are key pathways of programmed cell death and have been implicated in disease pathogen-
esis. Here, we reveal a RIP kinase 3 (RIPK3)-independent function of RIP kinase 1 (RIPK1) inmediating hepatocyte apoptosis
and triggering chronic hepatitis and HCC development. This function of RIPK1 depends on its kinase activity and is
controlled by nuclear factor kB (NF-kB)-dependent and NF-kB-independent NEMO functions. These results identify the
interplay between NEMO and RIPK1 as a key mechanism that is essential for hepatocyte survival and the prevention of
chronic liver damage leading to hepatocarcinogenesis.
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Figure 1. LPC-Specific NF-kB Inhibition Does Not Cause Similar Liver Damage as NEMO Deficiency
(A and B) Immunoblot analysis of liver (A) and hepatocyte (B) lysates from 8-week-old mice with the indicated genotypes. GAPDH and a-tubulin were used
as loading controls.
(C) Graph depicting basal serum ALT levels in 8-week-old mice with the indicated genotypes. Horizontal lines indicate mean values.
(legend continued on next page)
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steatohepatitis, and aflatoxin-mediated toxicity (Shariff et al.,
2009). Due to the limited treatment options, HCC is the third
most common cause for cancer-related deaths worldwide (El-
Serag, 2011; Shariff et al., 2009). Therefore, there is an urgent
need to better understand the mechanisms contributing to the
pathogenesis of chronic liver inflammation and HCC in order to
identify possible preventive strategies and therapeutic targets.
Death receptors, such as tumor necrosis factor receptor 1
(TNFR1), regulate cell death and inflammation and are implicated
in the pathogenesis of acute and chronic liver diseases and in
liver cancer (Schattenberg et al., 2011; Wang, 2014). Upon stim-
ulation, TNFR1 activates proinflammatory nuclear factor kB
(NF-kB) and mitogen-activated protein (MAP) kinase cascades
through a receptor-proximal signaling complex (complex I),
composed of TNFR1-associated death domain protein (TRADD),
receptor-interacting protein kinase 1 (RIPK1), as well as the E3
ubiquitin ligases TNF receptor-associated factor 2 (TRAF2),
cellular inhibitors of apoptosis 1 (cIAP1) and cellular inhibitors
of apoptosis 2 (cIAP2), and the linear ubiquitin chain assembly
complex (LUBAC) (Micheau and Tschopp, 2003; Walczak
et al., 2012). In sensitized cells (e.g., upon NF-kB inhibition),
complex I dissociates from the receptor and recruits Fas-associ-
ated via death domain protein (FADD) and caspase-8 to induce
apoptosis (Micheau and Tschopp, 2003). When caspase-8 is
inhibited, TNFR1 triggers necroptosis via receptor-interacting
protein kinase 3 (RIPK3) and mixed lineage kinase domain-like
protein (MLKL) (Vanden Berghe et al., 2014; Weinlich et al.,
2011). RIPK1 determines the outcome of TNFR1 signaling by
inducing pro-survival and proinflammatory signaling via kinase-
independent scaffolding functions, but also apoptosis or nec-
roptosis through its kinase activity (Christofferson et al., 2014;
Pasparakis and Vandenabeele, 2015).
The IkB kinase (IKK)/NF-kB pathway regulates cell survival,
inflammation, and cancer (Ben-Neriah and Karin, 2011; Hayden
and Ghosh, 2012) and is implicated in the pathogenesis of hep-
atitis and HCC (Luedde and Schwabe, 2011; Sun and Karin,
2008). Mammalian cells express five NF-kB transcription factors,
RelA/p65, RelB, c-Rel, p50/p105, and p52/p100. RelA, c-Rel,
and RelB contain transactivation domains and are capable to
activate gene transcription. In resting cells, NF-kB dimers are
kept inactive by association with inhibitory IkB proteins. Upon
cell stimulation, the IKK complex, consisting of the IKK1/IKKa
and IKK2/IKKb kinases and the NEMO/IKKg regulatory subunit,
phosphorylates IkB proteins targeting them for proteasomal
degradation. Consequently, NF-kBdimers accumulate in the nu-
cleus where they regulate the transcription of many genes
involved in inflammation, cell growth, cell survival, and prolifera-
tion (Hayden and Ghosh, 2012; Pasparakis, 2009; Perkins,
2012).
Mouse model studies revealed important but contradictory
functions of IKK/NF-kB signaling in liver carcinogenesis. IkBa
super-repressor-mediated NF-kB inhibition in hepatocytes de-
layed HCC progression but not tumor initiation in the Mdr2/
mouse model of inflammation-driven liver carcinogenesis by
counteracting TNF-mediated tumor promotion in hepatocytes
(Pikarsky et al., 2004). In addition, hepatocyte-specific ablation
of IKK2 prevented hepatitis and liver tumorigenesis induced by
transgenic overexpression of lymphotoxin a/b by inhibiting LTb
receptor-mediated expression of chemokines and cytokines
(Haybaeck et al., 2009). These reports support a predominantly
tumor-promoting function of NF-kB in hepatocytes. In
contrast, other studies revealed tumor-suppressing functions
of IKK/NF-kB signaling in the liver. In a mouse model of dieth-
ylnitrosamine (DEN)-induced hepatocarcinogenesis, hepato-
cyte-specific ablation of IKK2 resulted in increased tumor
load due to enhanced DEN-induced liver damage and
compensatory proliferation of IKK2-deficient hepatocytes
(Maeda et al., 2005). Mice with liver parenchymal cell (LPC)-
specific ablation of NEMO (NEMOLPC-KO) spontaneously devel-
oped chronic steatohepatitis and HCC, further supporting a
tumor suppressing function of IKK/NF-kB signaling in hepato-
cytes (Luedde et al., 2007). The development of hepatitis
and HCC in NEMOLPC-KO mice is triggered by FADD- and
caspase-8-dependent apoptosis of NEMO-deficient hepato-
cytes (Ehlken et al., 2014; Liedtke et al., 2011; Luedde et al.,
2007). However, the molecular mechanisms by which NEMO
inhibits hepatocyte apoptosis, hepatitis and HCC remain
poorly understood.
Here, we addressed the role of NF-kB and RIPK1 signaling in
the pathogenesis of liver disease and cancer caused by NEMO
ablation in LPCs.
RESULTS
Inhibition of NF-kB Signaling in LPCs Does Not
Phenocopy NEMO Deficiency
To study whether NEMO deficiency triggered hepatitis and HCC
by inhibiting NF-kB, we generated and analyzed mice lacking
NF-kB subunits in LPCs (Figures 1A and 1B). As reported previ-
ously (Geisler et al., 2007; Luedde et al., 2008), RelALPC-KO mice
did not develop considerable liver pathology, although they
had slightly elevated alanine aminotransferase (ALT) levels
compared to wild-type mice at the age of 8 weeks (Figure 1C).
To assess possible functional redundancy between NF-kB fac-
tors, we generated mice with LPC-specific single or combined
deficiency of RelA, RelB, and c-Rel, hereafter referred to as
NF-kBLPC-KO.
To address the role of hepatocyte NF-kB signaling in protect-
ing the liver from endotoxin-induced injury, we compared the
response of NF-kBLPC-KO and NEMOLPC-KO mice to a dose of
LPS that does not induce considerable liver damage in wild-
type mice. RelA/c-RelLPC-KO and triple NF-kBLPC-KO mice
showed increased serum ALT levels after LPS injection
compared to RelALPC-KO animals, suggesting that c-Rel can
partly substitute pro-survival functions of RelA in hepatocytes
(Figure 1D). However, NEMOLPC-KO mice were considerably
more sensitive to endotoxin-induced liver damage showing
8-fold higher ALT levels compared to NF-kBLPC-KO animals.
(D) Graph depicting serum ALT levels in mice with the indicated genotypes before and 4 and 10 hr after LPS injection (mean ± SD).
(E) Representative images of liver sections from 8-week-old mice with the indicated genotypes that are stained with H&E or immunostained with the indicated
antibodies. Graphs depict quantification of indicated parameters (mean ± SD, n = 3–5 mice per genotype). Scale bars, 200 mm.
See also Figure S1.
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Figure 2. Mice with LPC-Specific NF-kB Inhibition Do Not Develop HCC
(A) Representative liver images from 52-week-old mice with the indicated genotypes. Scale bar, 1 cm.
(B) Liver to body weight (LW/BW) ratios in 52-week-old mice with the indicated genotypes. Horizontal lines indicate mean values.
(C) Serum ALT levels in 52-week-old mice with the indicated genotypes. The ALT values of NF-kBLPC-KO mice with very small (<2 mm diameter) macroscopically
visible nodules are marked in red.
(legend continued on next page)
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Surprisingly, 8-week-old RelALPC-KO, RelALPC-KO;c-RelLPC-KO,
and NF-kBLPC-KOmice had onlymildly elevated serumALT levels
(%100 U/l) that were 10-fold lower compared to NEMOLPC-KO
mice at this age (Figure 1C), showing that NF-kB inhibition was
not sufficient to cause substantial spontaneous liver damage.
Histological analysis of livers from 8-week-old NF-kBLPC-KO
mice revealed an overall normal liver architecture, with only a
limited number of apoptotic hepatocytes (Figure 1E). Interest-
ingly, in contrast to the NEMO-deficient livers that showed wide-
spread distribution of apoptotic hepatocytes throughout the liver
parenchyma, the few apoptotic hepatocytes in the livers of
NF-kBLPC-KO mice were localized mostly in the vicinity of focal
inflammatory cell infiltrates (Figure 1E). The limited hepatocyte
death in NF-kBLPC-KO livers correlated with a moderate increase
of Ki-67+ proliferating hepatocytes, which was significantly lower
than in NEMOLPC-KO livers and was not accompanied by hepatic
stellate cell (HSC) or liver progenitor cell activation, as shown by
immunostaining for a-smooth muscle actin (a-SMA) and cyto-
keratin 19 (CK19), respectively (Figures 1E and S1). Immunohis-
tochemistry revealed that macrophages, granulocytes, T cells,
and B cells populated the foci of dying hepatocytes in the livers
of NF-kBLPC-KO mice (Figures 1E and S1).
In contrast to NEMOLPC-KO mice, livers from 1-year-old mice
with individual or combined LPC-specific deficiency of RelA,
c-Rel, and RelB did not display macroscopic signs of tumor
development, and only 25% (6 out of 25) of NF-kBLPC-KO
mice showed a number of very small macroscopically visible
steatotic nodules (Figure 2A). Accordingly, liver-to-body weight
(LW/BW) ratio in NF-kBLPC-KO mice was similar to controls and
significantly lower than that of NEMOLPC-KO mice (Figure 2B).
One-year-old NF-kBLPC-KO mice showed significantly elevated
serum ALT levels compared to controls but on average lower
than NEMOLPC-KO mice (Figure 2C). Notably, ALT levels in
NF-kBLPC-KO mice with macroscopically visible liver nodules
were statistically higher compared to nodule-free mice (Fig-
ure 2C; 332 versus 135, p = 0.003), indicating that the appear-
ance of small steatotic nodules correlated with increased liver
damage.
Histologically, livers from 1-year-old NF-kBLPC-KO mice
showed a relatively normal overall architecture without signs of
HCC or preneoplastic lesions, with the macroscopically visible
nodules identified as focal fatty changes resembling clear cell
foci (Figures 2D, S2A, and S2B). Interestingly, collagen staining
by Masson’s trichrome showed that two-thirds of the examined
livers (n = 9) displayed periportal or bridging fibrosis (Figures 2D
and S2A). The areas of focal apoptosis observed in the liver of
8-week-old mice were also present at 1 year of age (Figures
2D, S2C, and S2D), but with higher frequency reflecting their
increased serum ALT values (Figure 2C). Hepatocyte prolifera-
tion was mildly elevated in NF-kBLPC-KO mice compared to
NF-kBFL littermates but lower than the non-tumor liver tissue of
NEMOLPC-KO mice (Figure 2D). Therefore, combined ablation of
RelA, RelB, and c-Rel in LPCs was not sufficient to cause spon-
taneous development of HCC as observed in NEMOLPC-KOmice,
suggesting that NEMO prevents liver tumorigenesis by functions
independent of NF-kB-mediated gene transcription.
Constitutively Active IKK2 Expression Prevents
Hepatocellular Damage andHCC in NEMOLPC-KOMice by
Activating NF-kB
Although NF-kB inhibition alone was not sufficient to cause liver
tumors, impairment of NF-kB could contribute to the liver pa-
thology of NEMOLPC-KO mice when combined with the loss of
NF-kB-independent NEMO functions. To address this possi-
bility, we examined whether enforced NF-kB activation in
NEMO-deficient hepatocytes induced by the overexpression of
a constitutively active IKK2 (IKK2ca) transgene (Sasaki et al.,
2006) could rescue the liver phenotype of NEMOLPC-KO mice.
Heterozygous expression of the R26-StopFL-IKK2ca transgene
in NEMOLPC-KO;IKK2caLPC mice resulted in 5-fold increased
IKK2 protein levels in the liver compared to endogenous IKK2
levels correlating with nuclear accumulation of RelA in hepato-
cytes (Figures 3A and S3A). Strikingly, serum ALT levels as
well as hepatocyte apoptosis and proliferation, myeloid
cell and HSC activation, and fibrosis were drastically reduced
in 8-week-old NEMOLPC-KO;IKK2caLPC mice compared to
NEMOLPC-KO (Figures 3B, 3C, and S3B, compare with Figures
1E and S1). Furthermore, NEMOLPC-KO;IKK2caLPC mice exam-
ined at the age of 12–16 months did not show macroscopically
visible liver nodules and had markedly lower LW/BW ratio
compared to NEMOLPC-KO mice (Figures 4A–4D). Histological
analysis confirmed the lack of dysplastic nodules in livers from
NEMOLPC-KO;IKK2caLPC mice (Figures 4E and S4A). Therefore,
overexpression of IKK2ca prevented chronic hepatocellular
damage and the development of HCC in NEMOLPC-KO mice.
To investigate how IKK2ca expression prevented the death of
NEMO-deficient hepatocytes, we prepared primary hepatocytes
from NEMOLPC-KO, NEMOLPC-KO;IKK2caLPC, and NF-kBLPC-KO
mice. NEMO-deficient, but not NF-kB-deficient, primary hepato-
cytes underwent spontaneous apoptosis in culture that could be
prevented by treatment with z-VAD-fmk and was only partially
reduced by TNF blockade (Figure S4B). Consistent with its
protective effect in vivo, IKK2ca expression prevented the spon-
taneous death of primary NEMO-deficient hepatocytes in vitro
(Figure S4B). Assessment of NF-kB activation in z-VAD-fmk-
treated primary hepatocytes confirmed that IKK2ca induced
constitutive nuclear accumulation of RelA (Figure S4C), suggest-
ing that RelA-mediated expression of anti-apoptotic genes could
prevent the death of NEMO-deficient hepatocytes. To address
this possibility, we generated and analyzed NEMOLPC-KO mice
that expressed IKK2ca but at the same time lacked RelA
specifically in LPCs (NEMOLPC-KO;RelALPC-KO;IKK2caLPC mice)
(Figure 3A). NEMOLPC-KO;RelALPC-KO;IKK2caLPC mice showed
elevated serum ALT levels and increased hepatocyte apoptosis,
immune cell infiltration, compensatory hepatocyte proliferation,
activation of HSCs, and fibrosis (Figures 3B, 3C, and S3B),
revealing that IKK2ca expression could not prevent spontaneous
liver damage in NEMOLPC-KO mice in the absence of RelA.
(D) Representative images of liver sections from 52-week-old NF-kBLPC-KO, NEMOLPC-KO and floxed control mice stained with Masson’s trichrome (collagen
staining in blue) or immunostained with the indicated antibodies. HCC areas are outlined and marked with an asterisk. Graph shows quantification of Ki67+ cells
(mean ± SD, n = 3–5 mice per genotype). Scale bars, 200 mm.
See also Figure S2.
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Figure 3. Overexpression of Constitutively Active IKK2 Prevents Spontaneous Liver Damage in NEMOLPC-KO Mice by Activating NF-kB
(A) Liver lysates from mice with the indicated genotypes were analyzed by immunoblot with the indicated antibodies. a-Tubulin was used as loading control.
(B) Graph depicting basal serum ALT levels in 8- and 52-week-old mice with the indicated genotypes. Horizontal lines indicate mean values.
(C) Representative images of liver sections from 8-week-old mice with the indicated genotypes after staining with H&E or immunostaining with the indicated
antibodies. Graphs depict quantification of the indicated parameters (mean ± SD, n = 3–5 mice per genotype). Scale bars, 200 mm.
See also Figure S3.
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Moreover, most 1-year-old NEMOLPC-KO;RelALPC-KO;IKK2caLPC
mice developed tumors with histopathological features of
HCCs, demonstrating that IKK2ca-mediated inhibition of HCC
development in NEMOLPC-KO mice depended on RelA (Figures
4A, 4E, and S4A). However, NEMOLPC-KO;RelALPC-KO;IKK2caLPC
mice showed reduced number and size of tumors compared to
NEMO
LPC-KO
;RelALPC-KO mice (Figures 4C and 4D), indicating
that RelA ablation could not completely counteract the protec-
tive effect of IKK2ca overexpression. Therefore, IKK2ca overex-
pression prevents liver damage and HCC in NEMOLPC-KO mice
mainly by inducing RelA-dependent canonical NF-kB activation.
To gain mechanistic insight into how NEMO prevents hepato-
cyte apoptosis, we first analyzed the expression of a number of
prosurvival genes in isolated hepatocytes from NEMOLPC-KO,
NF-kBLPC-KO and wild-type mice. Surprisingly, we found that
NEMO or NF-kB deficiency did not result in markedly reduced
mRNA expression of prosurvival genes, with the exception of
Sod2 that was downregulated in the liver of both NEMOLPC-KO
and NF-kBLPC-KO mice (Figure 4F). These results suggested
that apoptosis of NEMO-deficient hepatocytes is not caused
by an impaired transcriptional regulation of NF-kB-dependent
antiapoptotic genes, consistent with the findings that complete
NF-kB inhibition did not phenocopy NEMOdeficiency in the liver.
However, IKK2ca expression induced elevated mRNA expres-
sion of the anti-apoptotic proteins cIAP1, cIAP2, and A20, as
well as of the anti-oxidant enzyme SOD2 in NEMO-deficient
livers (Figure 4F). Curiously, IKK2ca did not increase the mRNA
expression of cFLIP and Bcl-xl that are considered important
transcriptional targets of NF-kB (Figure 4F). In addition, IKK2ca
reduced the expression of the proapoptotic protein Bax, which
is expressed at increased levels in NEMO-deficient livers. These
results suggested that IKK2ca expression prevents the death of
NEMO-deficient hepatocytes by inducing NF-kB-dependent
expression of anti-apoptotic and anti-oxidant genes.
NEMO-deficient hepatocytes did not show TNF-inducible
nuclear translocation of RelA but displayed strongly increased
constitutive nuclear accumulation of p50 (Figure S4C). More-
over, RelB was constitutively present in the nucleus of NEMO-
deficient hepatocytes at levels similar to those induced by TNF
in wild-type cells (Figure S4C). This correlated with a decreased
expression of cIAP1, whose degradation promotes non-canoni-
cal NF-kB activation (Sun, 2012). These findings prompted us to
investigate the potential role of non-canonical NF-kB signaling in
NEMOLPC-KO mice by generating NEMOLPC-KO;RelBLPC-KO mice.
However, RelB ablation did not inhibit spontaneous liver damage
and the development of hepatitis and HCC in NEMOLPC-KO mice
arguing against a role of non-canonical NF-kB signaling (Figures
S4D–S4G).
RIPK1 Kinase Activity-Dependent Apoptosis Drives
Hepatocyte Death and HCC Development in
NEMOLPC-KO Mice
RIPK1 and RIPK3 emerged recently as critical regulators of
cell death and inflammation. We therefore addressed the
role of RIP kinase-mediated signaling in the development of
hepatitis and HCC in NEMOLPC-KO mice. Eight-week-old
NEMOLPC-KO;Ripk3/ mice showed elevated ALT levels,
increased apoptosis, and compensatory proliferation of hepato-
cytes, as well as immune cell infiltration in the liver similarly to
NEMOLPC-KO;Ripk3WT/- mice (Figure S5A and data not shown).
In addition, macroscopic and histological analysis of livers
from 1-year-old mice revealed that RIPK3 deficiency did not pre-
vent the development of HCC in NEMOLPC-KO mice (Figures
S5B–S5E). Therefore, RIPK3-dependent necroptosis does not
contribute to the spontaneous liver pathology of NEMOLPC-KO
mice.
Inhibition of RIPK1 kinase activity by necrostatin-1 or other
small molecule inhibitors prevents RIPK3/MLKL-dependent
necroptosis and under certain conditions apoptosis (Christoffer-
son et al., 2014; Pasparakis and Vandenabeele, 2015; Vanden
Berghe et al., 2014). To address the role of RIPK1 kinase activity
in hepatocyte death and HCC development in NEMOLPC-KO
mice, we crossed them to knock-in mice expressing a kinase-
inactive mutant RIPK1 (RIPK1D138N) (Polykratis et al., 2014).
Strikingly, 8-week-old NEMOLPC-KO;Ripk1D138N/D138N mice
showed strongly reduced serum ALT levels compared to
NEMOLPC-KO mice (Figure 5A). Immunoblot analysis showed
lack of caspase-3 and JNK activation in liver extracts from
8-week-old NEMOLPC-KO;Ripk1D138N/D138N mice (Figure 5B).
Accordingly, histological analysis of livers from NEMOLPC-KO;
Ripk1D138N/D138N mice showed significantly reduced hepatocyte
apoptosis and proliferation and HSC activation compared to
NEMOLPC-KO mice (Figure 5C). To exclude the possibility that in-
hibition of RIPK1 kinase activity in a cell type different from
LPCs was responsible for the protective effect, we generated
NEMOLPC-KO mice carrying one loxP-flanked Ripk1 allele and
one Ripk1D138N allele. In these mice, Alfp-Cre-mediated deletion
of the floxed Ripk1 allele results in expression of only the
RIPK1D138N protein in LPCs, while all other cells express both
wild-type RIPK1 and the mutant RIPK1D138N protein. Similarly
to NEMOLPC-KO;Ripk1D138N/D138N mice, these NEMOLPC-KO;
RIPK1LPC-KO/D138N mice showed strongly reduced liver damage
(Figure 5A and data not shown). Collectively, these results
showed that lack of RIPK1 kinase activity strongly protected
NEMO-deficient hepatocytes from apoptosis.
To further dissect the role of the kinase activity-dependent and
scaffolding functions of RIPK1 in hepatocyte death, we gener-
ated mice lacking both NEMO and RIPK1 in the liver by crossing
NemoFL/FL;Alfp-Cre mice with Ripk1FL/FL mice. Surprisingly,
8-week-old NEMOLPC-KO;RIPK1LPC-KO mice showed increased
serum ALT levels compared to NEMOLPC-KO;Ripk1D138N/D138N
or NEMOLPC-KO;RIPK1LPC-KO/D138N mice, although their ALT
levels were reduced compared to NEMOLPC-KO animals
(Figure 5A). Accordingly, liver extracts from NEMOLPC-KO;
RIPK1LPC-KO mice showed activation of caspase-3 albeit at
reduced levels compared to NEMOLPC-KO mice (Figure 5B). In
addition, histological analysis showed substantial hepatocyte
apoptosis and proliferation, inflammation and HSC activation in
the liver of NEMOLPC-KO;RIPK1LPC-KO mice (Figure 5C).
RIPK1LPC-KO mice did not show considerable liver damage and
displayed marginally elevated serum ALT levels and only sparse
focal hepatocyte apoptosis, suggesting that the liver damage in
NEMOLPC-KO;RIPK1LPC-KO is caused by the lack of NEMO and
not RIPK1 (Figures 5A and S5F).
In line with the reduced hepatocyte apoptosis in young
mice, 1-year-old NEMOLPC-KO;Ripk1D138N/D138N or NEMOLPC-KO;
RIPK1LPC-KO/D138N mice did not show macroscopic signs of liver
tumor development (Figures 6A–6C). Histological examination
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confirmed the lack of HCC or pre-neoplastic lesions and only
23% of the livers examined exhibited areas with clear cell foci
and anisokaryosis (Figures 6D and 6E). Interestingly, although
the livers of NEMOLPC-KO;Ripk1D138N/D138N did not show HSC
activation at 8 weeks, they exhibited mild portal fibrosis with
septa formation at the age of 1 year (Figure 6D). Analysis of
1-year-old NEMOLPC-KO;RIPK1LPC-KO mice revealed the devel-
opment of liver tumors with dysplastic foci, dysplastic nodules
and HCC, although macroscopically33% of the mice analyzed
(7 out of 20) had smaller nodules compared to NEMOLPC-KOmice
suggesting that RIPK1 deficiency inhibited tumor growth (Fig-
ures 6A–6E). Therefore, lack of RIPK1 kinase activity but not
the absence of RIPK1 protein prevented hepatocyte apoptosis
and HCC development in NEMOLPC-KO mice.
TRADD Mediates Apoptosis of NEMO-Deficient
Hepatocytes in the Absence of RIPK1
The differential effects of RIPK1 kinase activity inhibition versus
loss of its scaffolding functions suggested the existence of two
distinct pathways triggering hepatocyte death in NEMO-defi-
cient hepatocytes. When RIPK1 is present, its kinase activity is
required for hepatocyte apoptosis, but when RIPK1 protein is
absent, an alternative RIPK1-independent apoptotic pathway
is induced. Since TRADD was shown to induce RIPK1-indepen-
dent apoptosis (Vanlangenakker et al., 2011; Zheng et al., 2006),
we examined the role of TRADD in NEMOLPC-KO mice by gener-
ating mice lacking both NEMO and TRADD in LPCs (Figure S6A).
Analysis of serum ALT levels at the age of 8 weeks showed that
LPC-specific TRADD deficiency did not prevent hepatocyte
death and hepatitis in NEMOLPC-KO mice (Figure S6B). Further-
more, macroscopic and histological examination of livers from
1-year-old NEMOLPC-KO;TRADDLPC-KO mice revealed the devel-
opment of HCC or pre-neoplastic lesions, although the number
of macroscopically visible large tumors was decreased
compared to littermates that were heterozygous for TRADD (Fig-
ures S6B–S6G). Therefore, TRADD deficiency did not prevent
hepatocyte apoptosis and liver damage but partly inhibited liver
tumor growth in NEMOLPC-KO mice.
To assess whether TRADD triggers apoptosis in NEMO/RIPK1-
deficient hepatocytes, we generated NEMOLPC-KO;RIPK1LPC-KO;
TRADDLPC-KO mice (Figure 7A). Strikingly, caspase-3 activation
in the liver and serum ALT levels were strongly reduced
in 8-week-old NEMOLPC-KO;RIPK1LPC-KO;TRADDLPC-KO mice
compared to NEMOLPC-KO;RIPK1LPC-KO animals (Figures 7A
and 7B). Accordingly, histological analysis of livers from
NEMOLPC-KO;RIPK1LPC-KO;TRADDLPC-KO mice showed that
apoptosis, compensatory proliferation, HSC activation and hepa-
titis were all nearly completely restored back to wild-type levels
(Figure 7C). Moreover, 1-year-old NEMOLPC-KO;RIPK1LPC-KO;
TRADDLPC-KO mice did not develop liver tumors (Figures 6E and
7D–7F). Therefore, in the absence of RIPK1 scaffolding function,
TRADD-mediated apoptosis induces liver damage and HCC
development in NEMOLPC-KO mice.
RIPK1 and TRADD are known to induce apoptosis
downstream of TNFR1 via distinct protein complexes suggest-
ing that TNF might contribute to hepatocyte apoptosis in
NEMOLPC-KO mice. However, we showed previously that
LPC-specific ablation of TNFR1, Fas or TRAIL alone or in
combination did not prevent hepatocyte death and HCC devel-
opment in NEMOLPC-KO mice, arguing that apoptosis of
NEMO-deficient hepatocytes is not triggered by these death
receptors (Ehlken et al., 2014). Furthermore, in contrast to
a recent report (Cubero et al., 2013), we found that TNFR1
deficiency did not considerably diminish liver damage in
8-week-old NEMOLPC-KO;Tnfr1/ mice (Figures S6H–S6K).
One-year-old NEMOLPC-KO;Tnfr1/ mice had mildly reduced
ALT levels and LW/BW ratio compared to NEMOLPC-KO;
Tnfr1WT/-, and they developed a similar number of dysplastic
nodules although they lacked large tumors with histological
characteristics of HCC (Figures S6I–S6L). Therefore, global
TNFR1 deficiency did not prevent hepatocyte death and tumor
initiation but delayed tumor progression in NEMOLPC-KO mice.
These results show that TNF is not an essential driver of hepa-
tocyte apoptosis and tumor development in NEMOLPC-KO mice
and suggest that other, yet unidentified, TNF-independent
pathways trigger this liver pathology.
NEMO Prevents the Formation of a RIPK1/FADD/
Caspase-8 Complex in Hepatocytes
To gain mechanistic insight on how NEMO regulates RIPK1
kinase-mediated apoptosis, we analyzed the expression of pro-
teins regulating the formation of the FADD/caspase-8 signaling
complexes in NEMOLPC-KO mice. Expression of cFLIP, cIAP1,
and TRAF2 was considerably diminished in NEMO-deficient
livers and hepatocytes (Figures 8A and 8B). Notably, expression
of kinase inactive RIPK1D138N, but not RIPK1 ablation, fully
restored the expression of cFLIP and partly normalized the
expression of TRAF2 and cIAP1 proteins in the NEMO-deficient
livers (Figures 8A and 8B). Moreover, IKK2ca expression
restored the protein levels of cIAP1 andSOD2 inNEMO-deficient
livers (Figures 8C and S4C). Loss of cFLIP, cIAP1, and TRAF2
could trigger apoptosis in NEMO-deficient hepatocytes by pro-
moting the association of RIPK1 with FADD and caspase-8, as
shown for ripoptosome formation in response to DNA damage
(Tenev et al., 2011). Indeed, immunoprecipitation of RIPK1 and
subsequent immunoblotting with antibodies against FADD and
caspase-8 revealed that these proteins interacted with RIPK1
in NEMO-deficient hepatocytes (Figure 8D). Immunoprecipita-
tion of FADD confirmed the interaction of RIPK1 with FADD
and caspase-8 in NEMO-deficient hepatocytes (Figure 8E).
Importantly, expression of kinase inactive RIPK1D138N pre-
vented the association of FADD and caspase-8 with RIPK1 in
NEMO-deficient hepatocytes (Figures 8D and 8E), consistent
with the restored expression of cFLIP, cIAP1 and TRAF2 in the
liver of NEMOLPC-KO;Ripk1D138N/D138N mice. Collectively, these
results suggested that NEMO protects hepatocytes from death
(E) Representative images of Masson’s trichrome stained liver sections from 52-week-old mice with the indicated genotypes. HCC/dysplastic nodule areas are
marked with an asterisk. Scale bar, 200 mm.
(F) qRT-PCR analysis of anti-apoptotic and anti-oxidant gene expression in primary hepatocytes from the indicatedmice. Graphs show relativemRNA expression
normalized to Tbp.
See also Figure S4.
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by preventing the formation of a RIPK1/FADD/caspase-8
apoptosis-inducing complex.
DISCUSSION
The IKK/NF-kB signaling pathway has emerged as a key regu-
lator of liver homeostasis and disease. In particular, the finding
that mice with LPC-specific NEMO deficiency showed sponta-
neous hepatocyte apoptosis, chronic hepatitis and HCC sug-
gested a key function of NF-kB in preventing hepatocyte death
in the adult liver and development of liver cancer (Luedde
et al., 2007; Pasparakis, 2009). To overcome the functional
redundancy between NF-kB subunits, we studied the role of
NF-kB in the adult liver by generating mice with LPC-specific
ablation of all three NF-kB proteins capable of activating gene
transcription, namely RelA, c-Rel, and RelB, thereby completely
inhibiting NF-kB-mediated gene expression. Surprisingly, in
contrast to NEMOLPC-KO mice, NF-kBLPC-KO mice showed only
limited spontaneous hepatocyte apoptosis at young age and
although a fraction of these mice showed increased liver dam-
age, hepatitis, steatosis, and fibrosis at the age of 1 year they
did not develop liver tumors. NEMOLPC-KO mice showed much
more severe liver damage compared to NF-kBLPC-KO mice
both spontaneously and in response to LPS, demonstrating
that NEMO exhibits additional NF-kB-independent pro-survival
functions in hepatocytes. Considering that NF-kB inhibition did
not phenocopy NEMO deficiency, it was unexpected that over-
expression of IKK2ca could prevent hepatocyte death and
HCC development in NEMOLPC-KO mice. Our results that the
IKK2ca protective effect largely depended on RelA suggested
that IKK2ca prevented apoptosis of NEMO-deficient hepato-
cytes, at least in part, by inducing the NF-kB-dependent expres-
sion of pro-survival genes such as cIAP1, cIAP2, and A20.
Moreover, IKK2ca expression also restored the expression of
SOD2, which could protect NEMO-deficient hepatocytes from
oxidative stress. Collectively, these results showed that NEMO
ablation in LPCs triggers spontaneous hepatocyte death,
chronic hepatitis, and HCC by inhibiting both NF-kB-dependent
and NF-kB-independent pro-survival functions.
We showed previously that LPC-specific ablation of either
IKK2 or IKK1 did not cause spontaneous liver pathology, but
mice with combined IKK1/IKK2 or NEMO/IKK1 deficiency in
LPCs developed severe jaundice and fatal cholangitis character-
ized by inflammatory destruction of small portal bile ducts, sug-
gesting that combined inhibition of canonical and non-canonical
NF-kB signaling resulted in cholestatic liver disease (Luedde
et al., 2008). However, NF-kBLPC-KO and NEMOLPC-KO;
RelBLPC–KO mice did not develop a similar biliary phenotype,
suggesting that NF-kB-independent functions of IKK subunits
control bile duct integrity in the liver.
Our results revealed important but opposing RIPK1 kinase-
dependent and -independent functions in regulating liver dis-
ease in NEMOLPC-KO mice. Genetic inhibition of RIPK1 kinase
activity strongly reduced hepatocyte death, thereby preventing
liver damage and HCC development in NEMOLPC-KO mice.
RIPK1 kinase activity induces both apoptosis and necroptosis
(Pasparakis and Vandenabeele, 2015). However, RIPK3 defi-
ciency did not prevent hepatitis and HCC development in
NEMOLPC-KO mice, arguing that RIPK3/MLKL-driven necropto-
sis does not play an important role in this model. Moreover,
most dying hepatocytes in NEMOLPC-KO mice stain positive for
active caspase-3 and ablation of FADD or caspase-8 strongly
inhibited hepatocyte death and prevented HCC development
in these mice (Ehlken et al., 2014; Liedtke et al., 2011; Luedde
et al., 2007). Together, these results show that RIPK1-mediated
hepatocyte apoptosis causes chronic liver disease and HCC in
NEMOLPC-KO mice. However, RIPK1 ablation could not prevent
the death of NEMO-deficient hepatocytes showing that kinase-
independent scaffolding properties of RIPK1 are required to
prevent hepatocyte apoptosis. Remarkably, combined LPC-
specific deficiency of RIPK1 and TRADD, but not of TRADD
alone, prevented hepatocyte apoptosis and HCC development
in NEMOLPC-KO animals. RIPK1 and TRADD have been sug-
gested to trigger TNFR1-mediated apoptosis via distinct
signaling complexes, the TRADD-dependent complex IIa and
the RIPK1-dependent complex IIb (Christofferson et al., 2014;
Vanden Berghe et al., 2014; Wang et al., 2008). Although
TNFR1 deficiency did not prevent liver damage in NEMOLPC-KO
mice, it remains unclear whether TNFR1 signaling might
contribute to TRADD-dependent hepatocyte death in mice lack-
ing both NEMO and RIPK1 in LPCs.
NEMO-deficient as well as NF-kB-deficient livers did not show
considerably reduced transcription of anti-apoptotic genes,
revealing that NF-kB-dependent transcriptional regulation is
not essential to protect the adult liver under physiological condi-
tions. However, NEMO deficiency resulted in reduced protein
expression of cFLIP, cIAP1, and TRAF2 suggesting that NEMO
inhibits hepatocyte apoptosis, at least in part, by preventing
the degradation of these anti-apoptotic proteins. Furthermore,
immunoprecipitation experiments revealed that a RIPK1/
FADD/Caspase-8 signaling complex formed spontaneously in
NEMO-deficient hepatocytes. Remarkably, expression of kinase
inactive RIPK1D138N prevented the degradation of cFLIP,
cIAP1, and TRAF2 and the formation of the RIPK1/FADD/Cas-
pase-8 complex in NEMO-deficient livers. Single or combined
knockout of TNFR1, Fas or TRAILR1 did not prevent liver dam-
age and tumor development in NEMOLPC-KO mice (Ehlken
et al., 2014), suggesting that alternative signals drive the forma-
tion of the RIPK1/FADD/caspase-8 apoptosis-inducing complex
in NEMO-deficient hepatocytes. It is tempting to speculate that
loss of cIAPs and cFLIP may lead to the assembly of a complex
resembling the ripoptosome, which forms in response to DNA
damage or SMAC-mimetic-induced cIAP degradation (Tenev
et al., 2011). Ripoptosome formation was negatively regulated
by cFLIP and required RIPK1 kinase activity, further supporting
that similar mechanisms may trigger the formation of the
RIPK1/FADD/caspase-8 complex inducing hepatocyte
apoptosis in NEMOLPC-KO mice. However, it remains unclear
(D and E) Representative images of livers (D) and Masson’s trichrome stained liver sections (E) from 52-week-old mice with the indicated genotypes. Scale
bars, 1 cm (D); 200 mm (E).
(F) Tumor load quantification by LW/BW ratios. Horizontal lines indicate mean values.
See also Figure S6.
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Figure 8. NEMO Prevents the Degradation of cFLIPL, cIAP1, and TRAF2 and the Formation of a RIPK1/FADD/Caspase-8 Complex
(A andB) Immunoblot analysis of cFLIPL, cIAP1 and TRAF2 in liver lysates (A) and primary hepatocytes cultured in vitro in the presence of z-VAD-fmk (B) frommice
with the indicated genotypes. a-Tubulin and actin were used as loading controls.
(C) Immunoblot analysis of SOD2 in primary hepatocytes from mice with the indicated genotypes.
(D and E) Immunoblotting of RIPK1- (D) and FADD-containing (E) complexes immunoprecipitated from primary hepatocytes from mice with the indicated
genotypes cultured for 20 hr in the presence of z-VAD-fmk. GAPDH was used as loading control. ns, non-specific band.
(F) Proposed model for the interplay between NEMO, NF-kB, and RIPK1 in the regulation of hepatocyte survival and death.
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whether upstream receptors or other stress response pathways
are involved in triggering the loss of cIAPs and cFLIP and induc-
tion of apoptosis in NEMO-deficient hepatocytes.
NEMOwas previously reported to prevent TNF-induced death
of Jurkat T cells by inhibiting RIPK1-mediated activation of cas-
pase-8 independently of NF-kB (Legarda-Addison et al., 2009).
However, themolecular mechanisms bywhich NEMOdeficiency
induces cell death in Jurkat cells and hepatocytes are funda-
mentally different. In particular, TNF-induced apoptotic death
of NEMO-deficient Jurkat cells was prevented by RIPK1 but
not by FADD knockdown (Legarda-Addison et al., 2009). In
sharp contrast, the death of hepatocytes, as well as the develop-
ment of hepatitis and HCC in NEMOLPC-KO mice, were rescued
by the ablation of FADD (Ehlken et al., 2014; Luedde et al.,
2007) but not of RIPK1 (this study). Additionally, inhibition of
RIPK1 kinase activity by Nec-1 did not inhibit TNF-induced
apoptosis but prevented TNF+z-VAD-fmk-induced necroptosis
of NEMO-deficient Jurkat cells (O’Donnell et al., 2012). In
contrast, we showed that inhibition of RIPK1 kinase activity pre-
vented hepatocyte apoptosis in NEMOLPC-KO mice, while nec-
roptosis does not play a role in this model. Therefore, different
mechanisms regulate the TNF-induced death of NEMO-deficient
Jurkat T cells in vitro and apoptosis of NEMO-deficient hepato-
cytes in vivo.
Collectively, our results suggest that the interplay between
NEMO, RIPK1, and NF-kB determines the survival or death of
hepatocytes (Figure 8F). In wild-type livers, NEMO prevents
hepatocyte apoptosis by inhibiting the formation of the death-
inducing RIPK1/FADD/Caspase-8 signaling complex (complex
IIb). This function of NEMO is likely mediated, at least partly,
by preventing the RIPK1 kinase activity-dependent degradation
of cIAPs, TRAF2, and cFLIP. In addition, NEMO-mediated
NF-kB-dependent expression of SOD2 could also contribute to
the anti-apoptotic effect by reducing oxidative stress, as feeding
with the anti-oxidant butylated hydroxyanisole reduced liver
damage in NEMOLPC-KO mice (Luedde et al., 2007). In the
absence of NEMO, the RIPK1/FADD/Caspase-8 complex forms
in a RIPK1 kinase activity-dependent manner and induces
apoptosis. Enforced activation of NF-kB prevents apoptosis of
NEMO knockout hepatocytes most likely by inducing the
expression of pro-survival genes, such as cIAPs, A20, and
SOD2. Lack of RIPK1 kinase activity prevents apoptosis of
NEMO knockout hepatocytes by inhibiting the formation of the
RIPK1/FADD/Casp8 complex. However, lack of RIPK1 protein
removes not only its kinase-dependent but also its scaffolding
functions, which are important to prevent degradation of cFLIP,
cIAPs, and TRAF2, thereby promoting the formation of the
TRADD/FADD/Casp8 complex (complex IIa) inducing apoptosis
of NEMO-deficient hepatocytes.
Taken together, our results identify a NF-kB-independent
function of NEMO in controlling RIPK1 kinase activity-dependent
apoptosis of hepatocytes that is critical to prevent chronic liver
damage and HCC development in mice. These results suggest
that the interplay between NEMOand RIPK1 could be implicated
in chronic hepatitis and hepatocarcinogenesis in humans. Inter-
estingly, a recent study reported loss of NEMO immunoreactivity
in a significant percentage of human HCC samples, which corre-
lated with a poor 5-year overall survival (Aigelsreiter et al., 2012).
These findings suggest that loss of NEMO-dependent cytopro-
tective functions may be critical for the development of chronic
liver damage and HCC in at least a subset of patients. Hepato-
cyte death is a key feature of many chronic liver diseases, lead-
ing to inflammation, fibrosis, cirrhosis, and HCC development
(Luedde et al., 2014). Our results identify RIPK1 kinase activity
as a potent trigger of hepatocyte apoptosis that causes chronic
liver disease culminating in the development of HCC. Although
the role of RIPK1 in human liver disease remains unclear, it is
possible that RIPK1 kinase activity triggers hepatocyte death
in at least a subset of patients with chronic liver diseases leading
to HCC, such as viral hepatitis, alcoholic and non-alcoholic stea-
tohepatitis. Our results suggest that RIPK1 kinase inhibitors
could provide an effective and likely well-tolerated treatment op-
tion for such patients.
EXPERIMENTAL PROCEDURES
Mice
The following mouse lines were used: Rela/p65FL (Luedde et al., 2008), RelbFL
(Powolny-Budnicka et al., 2011), RelFL (Heise et al., 2014), NemoFL (Schmidt-
Supprian et al., 2000), R26IKK2casFL (Sasaki et al., 2006),Alfp-Cre (Kellendonk
et al., 2000), TraddFL (Ermolaeva et al., 2008), Ripk3/ (Newton et al., 2004),
Ripk1D138N (Polykratis et al., 2014), Ripk1FL (Dannappel et al., 2014), and
Tnfr1/ (Pfeffer et al., 1993). All alleles were maintained on a C57BL/6 genetic
background. Littermates carrying the floxed alleles but not the Alfp-Cre trans-
gene served as controls. Animals were housed in individually ventilated cages
in a specific pathogen-free (SPF) mouse facility at the Institute for Genetics,
University of Cologne, kept under a 12-hr light cycle, and given a regular
chow diet (Harlan, diet no. 2918) and water ad libitum. All animal procedures
were conducted in accordance with European, national and institutional
guidelines and protocols and were approved by local government authorities
(Landesamt fu¨r Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen,
Germany).
Mouse Experiments
LPS injections were performed on mice between 8 and 10 weeks of age. LPS
(Sigma) was administered intraperitoneally, at a concentration of 25 mg/10 g of
body weight, and blood was obtained prior to and 4 and 10 hr post injection.
ALT levels were measured in serum using a Cobas c111 analyzer (Roche).
Histology, Immunohistochemistry, and Quantification
H&E, Masson’s trichrome staining, immunohistochemistry (IHC), and staining
quantification was performed by standard procedures. For more detailed in-
formation, see the Supplemental Experimental Procedures.
Quantification of Macroscopically Visible Tumors and
Histopathological Evaluation
Livers of 1-year-old mice were excised, digitally photographed with their dor-
sal side exposed, and weighed to calculate the liver/body weight ratio. The
tumor number and size were determined by counting the number of visible
tumors/nodules and measuring their diameter using ImageJ. Histopatholog-
ical evaluation was performed as previously described (Ehlken et al., 2014)
and explained in detail in the Supplemental Experimental Procedures.
Hepatocyte Isolation and Cell Death Assays
Primary hepatocytes were isolated from 4-week-old mice and cultured in
DMEM (Sigma-Aldrich) containing 2% FCS, penicillin, and streptomycin. Cell
death was estimated using an LDH release-based cytotoxicity assay (Prom-
ega) according to the manufacturers’ instructions. For more detailed informa-
tion, see the Supplemental Experimental Procedures.
Immunoprecipitation, Subcellular Fractionation, and
Immunoblotting
Immunoprecipitation (IP) experiments were performed in primary hepatocytes
isolated from mice with the indicated genotypes and cultured for 20 hr in the
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presence of 20 mM zVAD-fmk. Subcellular fractionation, lysate preparation,
immunoprecipitation, and immunoblotting was performed using standard
protocols. For detailed description, see the Supplemental Experimental
Procedures.
Statistical Analysis
Data shown in column graphs represent themean ± SD, except tumor size dis-
tribution graphs that show the mean ± SEM. For those datasets that fulfilled
D’Agostino and Pearson normality test criteria an unpaired Student’s t test
was performed; otherwise nonparametric Mann-Whitney test was chosen.
*p% 0.05; **p% 0.01; ***p% 0.005. The analysis was performed using Prism
software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2015.10.001.
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